Latest News and Press Releases

New York, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today called the U.S. Food and Drug Administration’s approval of Itvisma (onasemnogene abeparvovec-brve),...

New York, Nov. 20, 2025 (GLOBE NEWSWIRE) -- This NFL season, during games in Weeks 12 and 13, hundreds of NFL players will step onto the field in custom-designed cleats as part of the 10th annual My...

Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved...

New York, Oct. 20, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today kicked off its largest annual MDA Holiday Retail Campaign, spanning thousands of retail locations...

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg...

New York, Feb. 27, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today that Robert Califf, MD, MAAC, former Commissioner of the U.S. Food and Drug Administration and...

New York, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today celebrates the decision by the US Food and Drug Administration (FDA) to grant approval of a risdiplam...

New York, Dec. 16, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the awarding of 21 new grants with a total funding commitment of over $5 million toward...

Positive study demonstrates the potential for investigational higher dose nusinersen regimen to advance the treatment of SMA; Biogen plans to submit for regulatory approval of this investigational...

Covina, Feb. 15, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Spinal Muscular Atrophy Market size was valued at about USD 1.4 Billion in 2024 and expected to grow at CAGR of...